project id: TCGA-PRAD; case submitter id: TCGA-J9-A52B; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.81; age at index: 62; days to birth: -22849; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1950; age at diagnosis: 22849; ajcc clinical t: T3b; ajcc pathologic n: N0; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 422.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 5; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; days to collection: 301; initial weight: 60.0; oct embedded: false; preservation method: Unknown; sample id: 0a64cc72-1f24-40d3-947f-5c38f2627fb7; sample submitter id: TCGA-J9-A52B-01A; portion id: 86c8bb51-8768-41fd-8198-c99572c2df3e; portion submitter id: TCGA-J9-A52B-01A-11; slide id: 9b88f2e9-4a87-4984-a87c-7c66d1cdd404; slide submitter id: TCGA-J9-A52B-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 5.0; percent stromal cells: 0.0; percent tumor cells: 95.0; percent tumor nuclei: 92.0; section location: TOP;